Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $141.6 million.

  • Silence Therapeutics' Shares Outstanding (Weighted Average) rose 1.06% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year increase of 1.06%. This contributed to the annual value of $141.6 million for FY2024, which is 22.10% up from last year.
  • As of FY2024, Silence Therapeutics' Shares Outstanding (Weighted Average) stood at $141.6 million, which was up 22.10% from $116.0 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Shares Outstanding (Weighted Average) registered a high of $141.6 million during FY2024, and its lowest value of $78.4 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $116.0 million (2023), whereas its average is $121.8 million.
  • Data for Silence Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increased of 22.10% (in 2024) over the last 5 years.
  • Silence Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $78.4 million in 2020, then grew by 14.55% to $89.8 million in 2021, then rose by 19.94% to $107.7 million in 2022, then increased by 7.74% to $116.0 million in 2023, then climbed by 22.10% to $141.6 million in 2024.